VANCOUVER, Feb. 23 /PRNewswire/ - Sirius Genomics, a developer of a pharmacogenomic test to identify potential responders to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris (R)), announced today that Bradley Popovich, President and CEO, will present at the annual Invest Northwest Investor-CEO forum conference on March 17, 2009 at 2:30 p.m. PST. The conference is presented by the Washington Biotechnology & Biomedical Association and will be at the Bell Harbor International Conference Center in Seattle.
About Invest Northwest: http://www.investnorthwest.org
An effective forum for senior executives from Pacific Northwest public and private life sciences companies to tell their stories to institutional investors, analysts, investment bankers, fund managers, venture capitalists, angel investors and prospective corporate partners.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that excels at developing pharmacogenomic (PGx) tests that lead to better patient outcomes through personalized medicine. Sirius' business focus is on generating value through improving the safety and effectiveness of pharmaceutical compounds. The Company's expert medical and business team correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
|SOURCE Sirius Genomics Inc.|
Copyright©2009 PR Newswire.
All rights reserved